The article provides an overview of the analyst ratings for NovoCure in the last quarter. The mixed ratings, with 3 bullish, 1 somewhat bullish, and 1 somewhat bearish, indicate that there is no clear consensus on the stock's short-term direction. The average 12-month price target has decreased by 4.44%, but this change is not significant enough to suggest a strong impact on the stock price in the short term.